Here’s what you should know:
1. The approval will be contingent upon Takeda divesting Shire’s gastrointestinal pipeline compound, Reuters reports. The compound overlaps with Takeda’s own inflammatory bowel disease drug, Entyvio.
2. Entyvio is Takeda’s biggest selling drug.
3. After earning EU approval, Takeda must earn shareholder approval.
4. Takeda scheduled a general meeting Dec. 5, to hold a shareholder vote, the Financial Times reports.
5. A portion of Takeda’s shareholders are vocal opponents of the deal, buta past procedural vote on the deal passed with little resistance.
More articles on supply chain:
HonorHealth plans to open $170M hospital, ASC in 2020 — 3 highlights
4 things surgeons should know when selecting an ASC for procedures
Medical Facilities Corp. increases surgical cases 47.4% in Q3 — 5 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
